The drug supply changed. Fentanyl is now in counterfeit pills that look exactly like Xanax or Percocet. Teens aren't seeking opioids. They're taking what a friend offers. One pill. What the ED sees that most families don't:

The cases I can't fix stay with me longer than the ones I can. That tension is what keeps the research honest. If you never feel the weight of the gap, you stop caring whether you close it.

Youth-led harm reduction works. Per SAMHSA data, peer outreach increases naloxone uptake among teens more than clinician-led programs. Adolescents trust each other. Investing in youth as health workers isn't just good optics. It's evidence-based public health strategy.

Clinicians counseling teens on cannabis are often working from evidence that's 5 to 10 years behind current potency levels. THC concentrations have risen sharply. The risk profile has shifted. The counseling hasn't.

Most evidence-based interventions never reach patients. Not because the science is wrong. Because implementation is its own science, and we treat it like an afterthought. The gap between what works in trials and what happens in clinics is enormous. What fills that gap:

Saw a 15-year-old last shift whose parents brought her in for "acting strange." Tox came back positive for opioids. She had no idea. Someone had given her something at a sleepover. The exposure wasn't a choice. It was the supply.

Children of parents with untreated SUD are 4 to 8 times more likely to develop addiction themselves per NIDA data. Family-based interventions change that trajectory. Not parenting tips. Structural treatment that addresses the whole unit. The family is a clinical variable.

PEM training teaches you to hold the acute and the structural at the same time. The seizing kid and the mold in the apartment. The ingestion and the parent who works nights. General EM sees the crisis. PEM is trained to see what created it.

Teens dying from fentanyl often had no history of opioid use. One pill. One night. But the conversation most families haven't had isn't about addiction. It's about the drug supply itself. What changed, and what it means:

I didn't come to this work from the outside. I came from shifts where the chart said one thing and the room said another. Research taught me to ask better questions. The bedside taught me which questions actually matter. That tension is where I live.

Cannabis legalization is outpacing what we actually know. Evidence on adolescent brain harm is real but incomplete. Clinicians counsel with confidence they don't have. Families assume legal means safe. The ED keeps seeing the gap between policy and evidence show up in real patients.

Funders love efficacy trials. Clean populations, controlled settings, clear endpoints. But that's not where care happens. What gets underfunded is the messy middle: training, workflow redesign, buy-in. That gap is where evidence goes to die.

Worked a shift where a teen came in seizing. Family thought it was epilepsy. Tox screen said fentanyl. He'd taken one pill. Thought it was a Perc. Never used opioids before that night. The ED is sometimes the first place a family learns what the drug supply actually is now.

A parent's untreated SUD during their teen's treatment isn't background context. Per family systems research, it's a primary outcome predictor. Treating the adolescent without addressing the family unit is treating half the patient.

The pediatric ED is where primary care gaps, housing instability, and mental health system failures all arrive at once, in crisis. A toddler with lead poisoning. A teenager who hasn't seen a doctor in four years. The ED visit is often the only contact point.

A teen with OUD who leaves the ED without buprenorphine is 4x more likely to return for another overdose per published outcomes data. We have the medication. We have the evidence. The barrier is clinician hesitation. What that costs in practice:

Most teens who die from fentanyl weren't using opioids. They took a counterfeit pill at a party. One time. The drug supply changed faster than public awareness did. What the ED keeps seeing:

386 overdose deaths in adolescents and young adults. The ED visit is a window. I wrote about 3 bedside tools that can make that window count. Practical, clinical, usable now. Read the full piece

A proven intervention can sit in a journal for 17 years before it reaches a real clinic. That's not an accident. It's a system that funds discovery and defunds delivery. What most people miss:

Naloxone works. But most families don't have it. Per CDC data, it reverses opioid overdose within minutes. The gap isn't the drug. It's distribution, stigma, and the myth that having it "enables" use. That myth costs lives. What the evidence actually shows:

Worked a shift last week where three separate teens came in for "anxiety attacks." All three had vaped something they couldn't name. None connected it to what they were feeling. The ED is often where substance use gets a diagnosis for the first time. That gap between use and recognition has a …

Parental SUD is one of the strongest heritable risk factors for adolescent addiction. Per family systems research, a parent in untreated recovery during their teen's treatment is a moderator so consistent it should change how we design interventions. The patient isn't just the kid.

Clinicians hesitate to prescribe buprenorphine to teenagers. Not because the evidence is weak. Because of discomfort, stigma, and a system not built for them. That hesitation has a clinical cost most people underestimate.

Teens don't overdose on fentanyl because they took too much. They overdose because the pill they thought was Xanax or Adderall was fentanyl. Counterfeit pills are now the primary vector. What the ED sees that never makes the news:

Buprenorphine works for adolescent OUD. The evidence is clear. But who actually gets it depends heavily on race, income, and geography. Not on severity. Not on clinical need. The data are striking:

Teens describe cannabis as "basically harmless." Parents often agree. Per NIDA surveys, clinicians frequently share that assumption. The clinical reality in the ED is different. Acute psychosis. Hyperemesis. Panic. The perceived safety gap is a counseling gap we haven't closed.

Funders love efficacy trials. Clean samples, controlled conditions, p<0.05. What they underinvest in is implementation. Getting an intervention to actually work in a real clinic, with real staff turnover and real Medicaid billing constraints. That gap is where evidence goes to die.

Most teens who overdose on fentanyl didn't know they took it. Per CDC data, over 75% of adolescent overdose deaths involve opioids, and the majority are accidental. Not experimentation gone wrong. Wrong pill entirely. What the ED sees that families rarely expect:

Family structure predicts teen SUD outcomes as strongly as individual risk. Per family systems research, parental recovery status during adolescent treatment is one of the most consistent moderators of success. Treating the parent isn't supplemental care. It's core pediatric intervention.

The teen in crisis waited 11 hours because there were no inpatient psych beds. The family with the lead-poisoned toddler had no PCP. The ED didn't fail them. Everything upstream did. We're just the last door still open.